Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Biota is a world-leading antiviral drug discovery company with its headquarters in Melbourne, Australia. Biota’s first breakthrough was the discovery of zanamivir, the first neuraminidase inhibitor, subsequently marketed by GlaxoSmithKline as Relenza for the treatment of influenza. In partnership with Thermo Electron, Biota markets the FLU OIA® diagnostics range for the rapid detection of influenza. In partnership with Sankyo, Biota is engaged in the development of second generation flu antivirals (LANI or Long Acting Neuraminidase Inhibitors). Biota also has active discovery and development programs aimed at new therapies for diseases caused by Human Rhinovirus (common cold), RSV (Respiratory Syncytial Virus), HIV, and hepatitis C. ( www.biota.com.au )
Biota Holdings Limited
Unit 10 585 Blackburn Road
Notting Hill, Victoria 3168
AUSTRALIA
Tel: +61 3 9915 3700
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. The Company’s initial development efforts are focused on gene therapy for treating Parkinson’s disease, epilepsy and Huntington’s disease. Neurologix’s core technology, “NLX,” is currently being tested in a Company-sponsored Phase I human clinical trial to treat Parkinson’s disease. ( www.neurologix.net )
Neurologix , Inc.
One Bridge Plaza
Fort Lee, New Jersey 07024
USA
Tel: (201) 592-6451
Fax: (201) 592-0366
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Microbia is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Microbia is committed to delivering new medicines into important markets with the goal of making a significant difference in patients’ lives. We create and advance innovative therapeutic agents by combining our unique R&D model of highly integrated pharmacology, chemistry, and biology with proven drugmaking practices. ( www.microbia.com )
Microbia , Inc.
320 Bent Street
Cambridge, Massachusetts 02141
USA
Tel: (617) 621-7722
Fax: (617) 494-0908
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Trigen previously announced the successful completion of a Phase I dose escalation study on TGN 167 using a classical rapid release tablet formulation. Trigen is developing TGN 167 for safe, effective, predictable and convenient anticoagulation for chronic out-patient use in the prevention and treatment of thrombosis. Trigen is a private UK biotechnology company, based in London, that discovers and develops novel drugs for the management of occlusive and inflammatory cardiovascular diseases. Trigen’s lead programme, comprising a series of anticoagulant direct thrombin inhibitors (DTIs) for the prevention and treatment of thrombosis, is in clinical development in both intravenous and oral ( www.trigen.co.uk )
Trigen Ltd
Clareville House 26-27 Oxendon Street
London SW1Y 4EL
United Kingdom
Tel: +44 20 7004 2630
Fax: +44 20 7004 2631
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting thrombolytic in Phase 3 clinical trials for the treatment of thrombotic-related disorders; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that recently completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short-acting anticoagulation during medical ( www.nuvelo.com )
Nuvelo , Inc.
675 Almanor Avenue
Sunnyvale, California 94085
USA
Tel: (408) 215-4000
Fax: (408) 215-4001
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
>VIRxSYS corporation is a private biotech company whose mission is to develop gene therapies using its proprietary lentiviral vector delivery system. The company is in Phase II clinical trials testing the first application of its gene therapy technology against HIV, VRX496. VIRxSYS also has collaborations for therapies in certain cancers and genetic diseases. The ability to safely and efficiently deliver genetic therapies has long been an obstacle to successful gene therapy, but VIRxSYS’s lentiviral vector is designed to deliver on the promise of genetic medicine. The Company expects that its genetic medicines will provide dramatically improved patient outcomes, including disease remission and may, possibly, provide permanent ( www.virxsys.com )
VIRxSYS Corporation
200 Perry Parkway Suite 1A
Gaithersburg, Maryland 20877
USA
Tel: (301) 987-0480
Fax: (301) 987-0489
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Item 1. Business Introduction Viragen, Inc. (which may be referred to as we, us or our) is a Delaware corporation organized in 1980. We are a biopharmaceutical company focused on the research, development, manufacture and commercialization of innovative technologies and products used to treat infectious diseases and cancers in humans. We are pioneering the science of avian transgenics whereby we intend to produce high quality proteins and antibodies in the egg whites of transgenic chi… ( www.viragen.com )
Viragen , Inc.
865 SW 78Th Avenue Suite 100
Plantation, Florida 33324-3212
USA
Tel: (954) 233-8746
Fax: (954) 233-1412
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Anacor, a privately held, clinical-stage pharmaceutical company, is developing novel product candidates for inflammatory and infectious diseases based on its proprietary, small-molecule, boron-based chemistry. Initially, Anacor is focusing development efforts on dermatological disorders with AN2690 in Phase 2 trials for onychomycosis, a fungal infection of nails and nailbeds. A second product candidate, AN0128, is in Phase 2 clinical trials for atopic dermatitis. ( www.anacor.com )
Anacor Pharmaceuticals
1060 East Meadow Circle
Palo Alto, California 94303-4230
USA
Tel: (650) 739-0700
Fax: (650) 739-0139
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStatÔ technology platform. The company’s lead product candidates for the treatment of Herpes labialis (cold sores) and onychomycosis (nail fungus) are in clinical trials. In addition, preclinical work is ongoing for a treatment for methicillin resistant Staphylococcus aureus (MRSA), and mucosal vaccines for influenza and Hepatitis B. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan. ( www.nanobio.com )
NanoBio Corporation
2311 Green Road Suite A
Ann Arbor, Michigan 48105
USA
Tel: (734) 302-4000
Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Cylene Pharmaceuticals, Inc. is a privately-held pharmaceutical company dedicated to the discovery, development and commercialization of first-in-class small molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. Cylene’s pipeline is led by CX-3543, a VEGF/c-Myc Oncogene Inhibitor currently in preclinical development. CX-3543 and other molecules in the pipeline originate from the company’s proprietary platform, which directs small molecules at molecular targets that regulate the expression of key oncogenes. The company is establishing its leadership position in small molecule regulation of oncogene expression by commercializing the pioneering work of two Cylene founders, Professors Laurence Hurley and Daniel Von Hoff. ( www.cylenepharma.com )
Cylene Pharmaceuticals , Inc.
5820 Nancy Ridge Drive Suite 200
San Diego, California 92121
USA
Tel: (858) 875-5100
Fax: (858) 875-5101